Company Happenings
Aardvark Therapeutics has been featured in numerous online resources and media sites.
Aardvark Therapeutics Expands Management Team with Two Key Hires
SAN DIEGO, Sept. 10, 2024 — Aardvark Therapeutics, Inc., a biopharmaceutical company, announced the appointment of Manasi Sinha Jaiman, M.D., M.P.H. as Chief Medical Officer and Tom Bicsak, Ph.D.,...
Interview with NYSE: Revolutionizing Obesity Treatment with ARD-101
Dr. Tien Lee, Founder and CEO of Aardvark Therapeutics, joined Judy Shaw on #NYSEFloorTalk to talk about their innovative obesity drug, ARD-101. He shared how...
Dr. Tien Lee, Founder and CEO of Aardvark Therapeutics, interviews on accomplishments with Nasdaq
Nasdaq Listings Host Kristina Ayanian delves into companies’ notable accomplishments, industry trends, and the driving factors behind their success through engaging conversations with C-suite executives...
Aardvark Therapeutics Announces $85 Million Oversubscribed Series C Financing
Series C financing led by Decheng Capital and supported by a syndicate of new and existing investors including Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon...
Biotech execs vie for a share of obesity drug boom: ‘It’s the early innings’
A link to the full article by STAT can be found here.
...Aardvark Therapeutics Announces Receipt of FDA Rare Pediatric Disease Designation for Prader-Willi Syndrome and Expands the Ongoing Phase 2 Clinical Trial
The FDA granted Aardvark Therapeutics a Rare Pediatric Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare genetic disease characterized by extreme...
